DRUG THERAPY FOR DIMINISHED MYOCARDIAL CONTRACTILITY

DOI: https://doi.org/10.29296/25877305-2018-06-03
Download full text PDF
Issue: 
6
Year: 
2018

Professor N. Mazur, MD; S. Miklishanskaya, Candidate of Medical Sciences Russian Medical Academy of Continuing Professional Education, Moscow

The paper gives data on drug therapy for patients with diminished myocardial contractility. There is evidence for its positive impact on survival. It is shown that especially when funding for free care is limited, it is important to use only the funds, the positive impact of which on the preservation of working capacity and life expectancy is proven.
Keywords: 
cardiology
evidence-based medicine
heart failure
left ventricular ejection fraction
life expectancy
nicorandil

It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

References: 
  1. Ponikowski P., Anker S., AlHabib K. et al. Heart failure: preventing disease and death worldwide // ESC Heart Failure. – 2014; 1: 4–25. DOI: 10.1002/ehf2.12005.
  2. Ceia F., Fonseca C., Mota T. et al. EPICA Investigators. Prevalence of chronic heart failure Southwestern Europe: the EPICA study // Eur. J. Heart Fail. – 2002; 4: 531–9.
  3. Ohlmeier C., Mikolajczyk R., Frick J. et al. Incidence, prevalence and 1-year all-cause mortality of heart failure in Germany: a study based on electronic healthcare data of more than six million persons // Clin. Res. Cardiol. – 2015; 104: 688–96. DOI: 10.1007/s00392-015-0841-4.
  4. Taichman D., Backus J., Baethge C. et al. Clinical Trial Data-A Proposal from the International Committee of Medical Journal Editors // N. Engl. J. Med. – 2016; 374 (4): 384–6.
  5. Mazur N.A. Prakticheskaja kardiologija / M.: Medpraktika-M, 2015; 679 s.
  6. Ponikowski P. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC // Eur. Heart J. – 2016; 37 (27): 2129–200. DOI: 10.1093/eurheartj/ehw128.
  7. Yancy C., Januzzi J. Jr, Allen L. et al. 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction // J. Am. Coll. Cardiol. – 2017; 71 (2): 201–30. DOI: 10.1016/j.jacc.2017.11.025.
  8. McMurray J., Packer M., Desai A. et al. Angiotensin-Neprilysin Inhibition versus Enalapril in Heart Failure // N. Engl. J. Med. – 2014; 371: 993–1004.
  9. Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure // N. Engl. J. Med. – 1997; 336 (8): 525–33.
  10. Swedberg K., Komajda M., Böhm M. et al. For the SHIFT Investigator. Effects on Outcomes of Heart Rate Reduction by Ivabradine in Patients With Congestive Heart Failure: Is There an Influence of Beta-Blocker Dose? Findings From the SHIFT (Systolic Heart failure treatment with the If inhibitor ivabradine Trial) Study // J. Am. Coll. Cardiol. – 2012; 59: 1938–45.
  11. Fox K., Ford I., Steg P. et al. SIGNIFY Investigators. Ivabradine in stable coronary artery disease without clinical heart failure // N. Engl. J. Med. – 2014; 371 (12): 1091–9.
  12. 2013 ACCF/AHA Guideline for the Management of Heart Failure // J. Am. Coll. Cardiol. – 2013; 62 (16): 147–239.
  13. Tice F., Binkley P., Cody R. et al. Hemodynamic effects of oral nicorandil in congestive heart failure // Am. J. Cardiol. – 1990; 65 (20): 1361–7.
  14. Zhao F., Chaugai S., Chen P. et al. Effect of nicorandil in patients with heart failure: a systematic review and meta-analysis // Cardiovasc. Ther. – 2014; 32 (6): 283–96. DOI: 10.1111/1755-5922.12097.
  15. Rjabihin E.A., Mozhejko M.E., Krasil'nikova Ju.A. i dr. Dopolnitel'nye vozmozhnosti v lechenii ishemicheskoj bolezni serdtsa, oslozhnennoj hronicheskoj serdechnoj nedostatochnost'ju s nizkoj fraktsiej vybrosa levogo zheludochka // Serdechnaja nedostatochnost'. – 2016; 17 (1): 3–9.
  16. Yoshihisa A., Sato Y., Watanabe S. et al. Decreased cardiac mortality with nicorandil in patients with ischemic heart failure // BMC Cardiovasc. Dis. – 2017; 17: 141–6.
  17. Nodari S., Triggiani M., Campia U. et al. Effects of n-3 polyunsaturated fatty acids on left ventricular function and functional capacity in patients with dilated cardiomyopathy // J. Am. Coll. Cardiol. – 2011; 57 (7): 870–9. DOI: 10.1016/j.jacc.2010.11.017.